Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2019-07-20 Regulatory Filings
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
The Company vide letter dated 22nd May 2019 had intimated that the Board of Directors had approved the proposal for raising funds upto Rs. 3000 crores by issue of non-convertible debentures ....
Regulatory Filings
2019-07-20 English
The Company vide letter dated 22nd May, 2019 had intimated that the Board of Directors had recommended payment of dividend of Rs. 3 per equity share (face value Rs. 2 per equity share) ....
Regulatory Filings
2019-07-20 English
Notice of the 83rd Annual General Meeting ('AGM') along with the copy of the Annual Report for the year ended 31st March, 2019
Regulatory Filings
2019-07-20 English
This is further to our letter dated 19th July 2019.The dates of inspection were inadvertently mentioned as 15th June 2019 to 19th June 2019 instead of 15th July 2019 to 19th July 2019. ....
Regulatory Filings Classification · 100% confidence The document contains only an omitted picture placeholder and no textual content. The true document length is only 54 characters, which is extremely short and contains no substantive information. It does not contain any financial data, report content, or announcements. Given the lack of content, it cannot be classified as any specific report or announcement type. The best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous or insufficient content filings.
2019-07-20 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (54 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report content, or any detailed information. Given the lack of content, this cannot be classified as a report or detailed filing. It is most consistent with a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-informative filings.
2019-07-20 English
We would like to inform you that the United States Food and Drug Administration (USFDA) conducted a routine cGMP inspection at our API manufacturing facility in Virgonangar, Bengaluru, ....
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 54 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, no report content, no announcements, or any other information to classify as a specific filing type. Given the lack of content, the document does not fit any specific category and defaults to the fallback category for miscellaneous filings.
2019-07-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.